Jorge Garcia, PharmD, MS, MHA, MBA, FACHE, Baptist Health South Florida, spoke about his panel held at the recent Institute for Value-Based Medicine® that The American Journal of Managed Care® cohosted with Providence Health System.
Jorge Garcia, PharmD, MS, MHA, MBA, FACHE, assistant vice president of system oncology and infusion pharmacy services, Baptist Health South Florida, spoke about his panel on ambulatory drug infusion that was featured at the recent Institute for Value-Based Medicine (IVBM) held in Newport Beach, California, cohosted by The American Journal of Managed Care and Providence Health System.
Transcript
What were you most looking forward to at the IVBM conference in Newport Beach?
I think what I'm most excited about is just coming together with colleagues to understand how they're working through different challenges and opportunities in their respective facilities and what I can bring back to my home institution to continue to advance health care.
What can attendees expect from your presentation on ambulatory drug infusion?
Over the years, I have sometimes gotten phone calls about patients who need nononcology infusion therapy. Sometimes the providers will call directly and they would ask me, "Help me find a share to infuse this patient, otherwise I may need to bring the patient through the Emergency Department. Or even worse, I may need to get the patient admitted."
As we know, that's not ideal, using those acute health care resources for an infusion that could otherwise be provided to the patient in the ambulatory setting. So with that vision in mind, we have put in practice a new service line that looks at ambulatory infusions for patients. Now we've operated the centers for 3 years, and we've learned a lot along the way; we've definitely opened access. We would love to share our experiences, our successes, and the challenges that we continue to work through to ensure that there is good access to nononcology infusion medicines in our community.
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More